Drug Trial Radar · NCT07543796
Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb)
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Apr 12, 2026
Primary completion
Dec 14, 2026
Study completion Apr 25, 2027
Sponsor
- Lead sponsor
- Beijing Tide Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase IIa, multicenter ,randomized, double-blind, Double-Dummy, Active- and placebo-controlled study designed to evaluate the efficacy, safety and kinetic characteristics of TRD205 tablets for postoperative analgesia after unilateral hip arthroplasty
Conditions
- Postoperative Analgesia After Unilateral Hip Arthroplasty
Interventions
TRD205 Tablets, oral; 400 mg initial dose, then 200 mg q12h for 3 doses; total 4 dosesDrug
First dose 2-4 hours before anesthesia induction; subsequent doses q12h (±4 hours window if nighttime)
TRD205 Tablets, oral; 800 mg initial dose, then 400 mg q12h; total 4 dosesDrug
First dose 2-4 hours before anesthesia induction; subsequent doses q12h (±4 hours window if nighttime)
TRD205 Tablets, oral; 1200 mg initial dose, then 600 mg q12h; total 4 dosesDrug
First dose 2-4 hours before anesthesia induction; subsequent doses q12h (±4 hours window if nighttime)
Celecoxib, oral; 400 mg initial dose, then 200 mg q12h; total 4 dosesDrug
First dose 2-4 hours before anesthesia induction; subsequent doses q12h (±4 hours window if nighttime)
Matching placebo tablets and capsules, same dosing scheduleDrug
First dose 2-4 hours before anesthesia induction; subsequent doses q12h (±4 hours window if nighttime)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the pain intensity-time curve (AUC0-48h) of resting pain NRS from 0 to 48 hours after surgeryTime frame: 0 to 48 hours after surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Third Affiliated Hospital of Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.